<![CDATA[Hansa Biopharma — Oktober 2022]]>Test.

]]>https://dev.proinvestor.com/forum/topic/400731/hansa-biopharma-oktober-2022RSS for NodeSat, 06 Jun 2026 11:35:01 GMTSun, 02 Oct 2022 05:42:23 GMT60<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Fri, 28 Oct 2022 11:34:20 GMT]]>Op ?

]]>https://dev.proinvestor.com/forum/post/8006366https://dev.proinvestor.com/forum/post/8006366Fri, 28 Oct 2022 11:34:20 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Fri, 21 Oct 2022 13:27:49 GMT]]>Hansa Biopharma: Klaus Sindahl, Head of Investor Relations presenterar på Redeye Investor AW – Göteborg 20 oktober 2022:

Just a moment...

favicon

(www.redeye.se)

(Redeye)

]]>https://dev.proinvestor.com/forum/post/8006369https://dev.proinvestor.com/forum/post/8006369Fri, 21 Oct 2022 13:27:49 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 04:36:36 GMT]]>... da HB jo har lukket mange aftaler på det sidste

]]>https://dev.proinvestor.com/forum/post/8006368https://dev.proinvestor.com/forum/post/8006368Thu, 20 Oct 2022 04:36:36 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 04:36:02 GMT]]>Det rigtige prisleje er vel fundet, da HB jo lukket mange aftaler på det sidste.

]]>https://dev.proinvestor.com/forum/post/8006363https://dev.proinvestor.com/forum/post/8006363Thu, 20 Oct 2022 04:36:02 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 04:34:17 GMT]]>"Sjukhusinköp ombeds återuppta förhandlingarna med leverantör", skriver myndigheten enligt Dagens Medisin."

Prøver velsagtens at opnå en bedre pris.

]]>https://dev.proinvestor.com/forum/post/8006362https://dev.proinvestor.com/forum/post/8006362Thu, 20 Oct 2022 04:34:17 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 04:29:00 GMT]]>Jaa, det er da i hvert fald en del højere end hvad jeg havde turde håbe på. Signifikant stigning i R&D, men det må man simpelthen ikke være bange for når man investerer i biotek. Jeg ser intet negativt i dette regnskab. For at snakke om noget andet, den manglende godkendelse i Norge. Er der nogen der ved yderligere? Det virker umiddelbart mystisk at Norge skulle gå mod alle andre i Europa?

]]>https://dev.proinvestor.com/forum/post/8006367https://dev.proinvestor.com/forum/post/8006367Thu, 20 Oct 2022 04:29:00 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 04:19:07 GMT]]>I forhold til "Consensus estimates" så er indtægterne absolut til den rigtig høje side.

Revenue: Q3 2022 SEKm 67.1 - 9M 2022 SEKm 123.8

]]>https://dev.proinvestor.com/forum/post/8006370https://dev.proinvestor.com/forum/post/8006370Thu, 20 Oct 2022 04:19:07 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 04:08:40 GMT]]>Upcoming milestones and news flow

2022 Anti-GBM: Initiation of phase 3 study

2022 NiceR: Completion of GLP tox studies

H2 2022 AMR Phase 2 study: First data read out

H2 2022 U.S. Kidney transplantation: Complete enrollment

H2 2022/H1 2023 GBS Phase 2 study: Complete enrollment

H1 2023 U.S. Kidney transplantation: Complete randomization

H2 2023 GBS Phase 2 study: First data read out

2023 Long-term follow-up data 5-years out in kidney transplantation

2024 Kidney transplantation US: BLA s

]]>https://dev.proinvestor.com/forum/post/8006359https://dev.proinvestor.com/forum/post/8006359Thu, 20 Oct 2022 04:08:40 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 04:03:59 GMT]]>
Link Preview Image
Hansa Biopharma Interim report January-September 2022 | Hansa Biopharma

favicon

(www.hansabiopharma.com)

]]>https://dev.proinvestor.com/forum/post/8006371https://dev.proinvestor.com/forum/post/8006371Thu, 20 Oct 2022 04:03:59 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 04:03:37 GMT]]>Hansa Biopharma Interim report January-September 2022

· Total Revenue of SEK 67m in the third quarter 2022
· Positive reimbursement decisions received in Poland and Scotland
· $70 million raised in non-dilutive financing
· Imlifidase included in ESOT guidelines published in Transplant International

]]>https://dev.proinvestor.com/forum/post/8006360https://dev.proinvestor.com/forum/post/8006360Thu, 20 Oct 2022 04:03:37 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Thu, 20 Oct 2022 03:54:29 GMT]]>Tisdagen den 18 oktober 2022 kl. 12:59. STOCKHOLM (Nyhetsbyrån Direkt) Hansa Biopharma har fått ett negativt besked gällande ett godkännande av imlifidase i Norge. Det rapporterar norska Dagens Medisin.

https://www.swedbank-aktiellt.se/telegram/uNEZorau

]]>https://dev.proinvestor.com/forum/post/8006356https://dev.proinvestor.com/forum/post/8006356Thu, 20 Oct 2022 03:54:29 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Mon, 17 Oct 2022 07:39:05 GMT]]>Hej er der nogen der ved hvornår fase 3 i Anti GBM studiet forelægger ??

]]>https://dev.proinvestor.com/forum/post/8006364https://dev.proinvestor.com/forum/post/8006364Mon, 17 Oct 2022 07:39:05 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Sun, 16 Oct 2022 06:17:02 GMT]]>Hansa Biopharma - Oversigt over analytikere og kursmål https://www.proinvestor.com/boards/106987

]]>https://dev.proinvestor.com/forum/post/8006354https://dev.proinvestor.com/forum/post/8006354Sun, 16 Oct 2022 06:17:02 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Fri, 14 Oct 2022 16:40:15 GMT]]>D. 20 oktober 2022 - Interim Report for January-September 2022 (næste torsdag).

]]>https://dev.proinvestor.com/forum/post/8006358https://dev.proinvestor.com/forum/post/8006358Fri, 14 Oct 2022 16:40:15 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Tue, 11 Oct 2022 06:56:14 GMT]]>opdatering

]]>https://dev.proinvestor.com/forum/post/8006365https://dev.proinvestor.com/forum/post/8006365Tue, 11 Oct 2022 06:56:14 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Tue, 04 Oct 2022 13:19:30 GMT]]>@B.Andersen - tak!

]]>https://dev.proinvestor.com/forum/post/8006357https://dev.proinvestor.com/forum/post/8006357Tue, 04 Oct 2022 13:19:30 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Tue, 04 Oct 2022 02:49:49 GMT]]>Hansa Biopharma - Q3 Update fra SEB https://proinvestor.com/boards/106667

]]>https://dev.proinvestor.com/forum/post/8006355https://dev.proinvestor.com/forum/post/8006355Tue, 04 Oct 2022 02:49:49 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Mon, 03 Oct 2022 11:52:12 GMT]]>ser frem til en tiltrængt opdatering ved regnskab 20 oktober ...

]]>https://dev.proinvestor.com/forum/post/8006361https://dev.proinvestor.com/forum/post/8006361Mon, 03 Oct 2022 11:52:12 GMT<![CDATA[Reply to Hansa Biopharma — Oktober 2022 on Sun, 02 Oct 2022 05:54:20 GMT]]>ok hanse er her stadig når man leder i chatten, men hansa mangler så istedet i fanebladet sammen med de andre aktier..

]]>https://dev.proinvestor.com/forum/post/8006353https://dev.proinvestor.com/forum/post/8006353Sun, 02 Oct 2022 05:54:20 GMT